hormone replacement therapy for menopause
A single user reported that one year of HRT including testosterone reversed their severe osteoporosis.
Hypothesized mechanism
Estrogen and testosterone in HRT may restore bone mineral density by reducing bone resorption and supporting bone formation during menopause.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a community rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Independence (patient accounts): 0 distinct account(s) across 1 thread(s) (author handles unavailable — counting distinct posts).
Rigor
The claim specifies the intervention (HRT including testosterone), a timeframe (1 year), and an outcome (reversal of severe osteoporosis), but lacks doses, baseline/follow-up bone density values, or measurement details. This is moderate but not full specificity.
Specificity
The drug (HRT incl testosterone) and outcome (osteoporosis reversal) are both clear and explicitly linked. However, the outcome 'reversed' is not quantified, leaving the linkage somewhat imprecise.
Plausibility
Estrogen and testosterone are known to influence bone mineral density, and HRT is recognized to slow or improve bone loss in menopause. The reported improvement in osteoporosis fits the pharmacology well.
Consistency
With only one report there is no conflicting or confirming account to assess agreement. The timing (1 year) and intervention cohere internally, but no cross-report consistency can be evaluated.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Community reports. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 11 year of HRT incl T, and my severe osteoporosis has reversed! Community report · Reddit ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →